Table 2 Univariate and multivariate analysis for risk factors to moderate-severe dyspnea after 1 month and 12 months (P value).
From: Neuroleptics used in critical COVID associated with moderate-severe dyspnea after hospital discharge
Parameters | 1 month | 12 months | ||
|---|---|---|---|---|
P | OR (CI95%) | P | OR (CI95%) | |
Female sex | 0.39 | 1.47 (0.62–3.51) | 0.16 | 2.40 (0.77–8.10) |
Age | 0.05 | 1.03 (1.00-1.08) | 0.29 | 1.02 (0.97–1.08) |
Charlson index | 0.04 | 1.20 (1.01–1.47) | 0.11 | 1.19 (0.96–1.49) |
Frailty pre-COVID | 0.52 | 1.13 (0.76–1.72) | 0.14 | 1.48 (0.88–2.60) |
Corticoids (quartiles) | < 0.01 | 1.80 (1.18–2.82) | 0.47 | 1.18 (0.72–1.98) |
Neuroleptics (quartiles) | < 0.01 | 1.94 (1.33–2.92) | 0.48 | 1.20 (0.76–1.89) |
Muscle blocker days | 0.28 | 1.10 (0.96–1.28) | 0.19 | 0.90 (0.73–1.07) |
Fentanyl days | 0.13 | 1.06 (0.99–1.15) | 0.36 | 0.96 (0.86–1.05) |
Midazolam days | 0.36 | 1.04 (0.96–1.14) | 0.46 | 0.96 (0.85–1.07) |
Noradrenaline days | 0.14 | 1.07 (1.00-1.17) | 0.87 | 0.99 (0.88–1.10) |
Time in mechanical ventilation | 0.24 | 1.03 (0.99–1.08) | 0.81 | 0.99 (0.93–1.05) |
Length of stay in ICU | 0.01 | 1.05 (1.01–1.10) | 0.73 | 0.99 (0.94–1.03) |
Length of stay in hospital | < 0.01 | 1.05 (1.02–1.09) | 0.50 | 1.01 (0.97–1.04) |
FVC (% of predicted) after 1 month from discharge | 0.09 | 0.97 (0.94–1.01) | 0,16 | 0.97 (0.93–1.01) |
Dyspnea 1 month after discharge | Not applicable | Not applicable | < 0.01 | 4.19 (2.07–10.2) |
Frailty 1 month after discharge | Not applicable | Not applicable | < 0.01 | 2.27 (1.29–4.42) |
